

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16  
Under the Securities Exchange Act of 1934**

**For the Month of March 2019**

**333-206723**  
**(Commission File Number)**

**P.V. Nano Cell Ltd.**  
(Exact name of Registrant as specified in its charter)

**8 Hamasger Street Migdal Ha'Emek, Israel 2310102**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**Additional Convertible Loan investment by prior investor - GTRIMG Investments Ltd.**

On October 23, 2018 P.V. Nano Cell Ltd. (the “**Company**”) published Form 6-K informing that on October 10, 2018 the Company entered into a convertible loan agreement (“**CLA**”) with GTRIMG Investments Ltd. (the “**Lender**”), in a principal loan amount of US \$1,000,000 which was provided at the closing of the CLA (the “**Principal Loan Amount**”). The Lender has an option to lend the Company an additional amount of up to US \$2,000,000 (the “**Additional Principal Amount**”) in effect until the earlier of: (i) repayment in full of the Principal Loan Amount, (ii) the conversion of the Principal Loan Amount (as described below), or (iii) a public offering of the Company's shares (“**PO**”). The conversion price and additional terms and details in connection with such CLA were disclosed in that Form 6-K.

On March 7, 2019 the lender provided additional \$500,000 on the account of the Additional Principal Amount.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**P.V. Nano Cell Ltd.**

Date: March 17, 2019

By: /s/ Fernando de la Vega

Name: Dr. Fernando de la Vega

Title: Chief Executive Officer